EUVIMEDEUVIMED entdecken
Crossref

Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix

Shuhei Kamada iD, Shinichi Sakamoto iD, Ryo Kinoshita, Xue Zhao, Tomohiko Kamasako, Ryosuke Yamase, Rii Junryo iD, Shinpei Saito, Pae Sangjon, Akinori Takei, Yasutaka Yamada iD, Yusuke Goto und 6 weitere

The Prostate · 2024

DOI: 10.1002/pros.24679 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2024. Verfasst von Shuhei Kamada und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan. Hauptthemen laut MEDLINE: Testosterone, Prostatic Neoplasms, Oligopeptides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Japan China Sasakawa Medical Fellowship (to X. Z.).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To clarify the clinical roles of changes in testosterone (T) levels with a cut‐off level of 20 ng/dL as predictive factors for prostate cancer patients treated with degarelix acetate.

Methods

A total of 120 prostate cancer patients who received hormone therapies with gonadotropin‐releasing hormone antagonist degarelix acetate were retrospectively analyzed. The predictive values of nadir T levels, max T levels, T bounce, and other clinical factors were evaluated for overall survival (OS), cancer‐specific survival (CSS), and progression‐free survival (PFS). T bounce was defined as satisfying both nadir serum T levels of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TestosteroneProstatic NeoplasmsOligopeptidesMaleHumansRetrospective StudiesPrognosisProstate-Specific AntigenGonadotropin-Releasing Hormone

Stichwörter der Autor:innen

degarelix acetateprostate cancertestosterone

Substanzen

Testosteroneacetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(…Prostate-Specific AntigenGonadotropin-Releasing HormoneOligopeptides

Autor:innen und Institutionen

  • Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.
  • Department of Urology, Saiseikai Utsunomiya Hospital, Utsunomiya, Japan.
  • Department of Urology, Funabashi Municipal Medical Center, Funabashi, Japan.
  • Department of Urology, Kanazawa Medical University, Kahoku-gun, Japan.
  • Department of Urology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
  • Department of Urology, Toho University Sakura Medical Center, Sakura, Japan.

ORCID-Profile: Shuhei Kamada, Shinichi Sakamoto, Rii Junryo, Yasutaka Yamada, Atsushi Mizokami

Förderung

  • Japan Society for the Promotion of Science
  • Japan China Sasakawa Medical Fellowship (to X. Z.)

Zitieren

APA

Kamada, S., Sakamoto, S., Kinoshita, R., Zhao, X., Kamasako, T., Yamase, R., Junryo, R., Saito, S., Sangjon, P., Takei, A., Yamada, Y., Goto, Y., Imamura, Y., Iguchi, T., Mizokami, A., Suzuki, H., Akakura, K., & Ichikawa, T. (2024). Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix. The Prostate. https://doi.org/10.1002/pros.24679

Vancouver

Kamada S, Sakamoto S, Kinoshita R, Zhao X, Kamasako T, Yamase R, et al. Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix. The Prostate. 2024. doi:10.1002/pros.24679

BibTeX
@article{Kamada2024,
  author = {Kamada, Shuhei and Sakamoto, Shinichi and Kinoshita, Ryo and Zhao, Xue and Kamasako, Tomohiko and Yamase, Ryosuke and Junryo, Rii and Saito, Shinpei and Sangjon, Pae and Takei, Akinori and Yamada, Yasutaka and Goto, Yusuke and Imamura, Yusuke and Iguchi, Taro and Mizokami, Atsushi and Suzuki, Hiroyoshi and Akakura, Koichiro and Ichikawa, Tomohiko},
  title = {Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix},
  journal = {The Prostate},
  year = {2024},
  doi = {10.1002/pros.24679}
}
Kostenlos starten →